Media Relations News Releases Year: - Any -20202019201820172016 Items per page 102550 Sep 12, 2018 Summary ToggleNovartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS Aug 27, 2018 Summary ToggleNovartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) Aug 25, 2018 Summary ToggleNovartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode Jul 30, 2018 Summary ToggleNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine prevention Jul 18, 2018 Summary ToggleNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Jun 29, 2018 Summary ToggleNovartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe Jun 28, 2018 Summary ToggleNovartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 27, 2018 Summary ToggleGlobal study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Jun 1, 2018 Summary ToggleNovartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine Pagination First page First Previous page Previous … Page 4 Current page 5 Page 6 Page 7 … Next page Next Last page Last
